Logo Image
Opinion|Videos|November 12, 2024

Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

Key Takeaways

  • Fezolinetant's approval was based on SKYLIGHT 1, 2, and 4 trials, which were randomized, double-blind, and placebo-controlled.
  • The trials focused on women with moderate to severe vasomotor symptoms, evaluating fezolinetant's safety and efficacy.
SHOW MORE

Panelists discuss the methodologies of the SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4 trials that supported the approval of fezolinetant for moderate to severe vasomotor symptoms (VMS) and examine the key safety and efficacy results derived from these studies.

Episodes in this series

Video content above is prompted by the following:

  1. (SMITH) The approval of fezolinetant for moderate to severe VMS was based on the SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4 trials. Briefly describe the methodology of these studies.
  2. (FIFFICK) What were the key safety and efficacy results from the SKYLIGHT studies?